The Tokyo District Court has dismissed a JPY 203.3 billion lawsuit filed by Northern TK Venture, an IHH Healthcare subsidiary, against Daiichi Sankyo. The case alleged that the Japanese pharma firm obstructed the 2018 Fortis Healthcare open offer. This ruling is a legal setback for IHH and adds to the uncertainty surrounding the long-running acquisition dispute involving Indian hospital assets.
On September 10, 2026, the Tokyo District Court issued a ruling dismissing the JPY 203.3 billion (approximately $1.25 billion) damages claim filed by Northern TK Venture (NTK) against the Japanese pharmaceutical major, Daiichi Sankyo. NTK, which is a wholly-owned subsidiary of the Malaysian healthcare giant IHH Healthcare, had initiated this litigation alleging that Daiichi Sankyo intentionally interfered with its 2018 open offer to acquire shares in Fortis Healthcare.
The court not only rejected the claims but also ordered NTK to bear all litigation costs associated with the case. This judgment concludes the current phase of a dispute that has been ongoing for several years, originating from the competitive environment during IHH’s entry into the Indian hospital sector. For IHH Healthcare, this ruling represents a significant legal and strategic setback, as the company had sought substantial compensation for alleged business obstruction during the high-profile acquisition.
Following the verdict, IHH Healthcare has indicated that it disagrees with the court's decision. The company is currently reviewing the judgment with its legal advisors to determine whether to pursue further appeals or explore other legal remedies. Daiichi Sankyo, on the other hand, has publicly stated that the court’s decision will not have a material impact on its financial results.
For investors monitoring Indian healthcare stocks, this development brings the focus back to the complex and often turbulent acquisition history of Fortis Healthcare. While IHH remains the controlling shareholder, the legal and regulatory landscape surrounding the company’s assets has been multifaceted. This Japanese court ruling adds to a backdrop of other legal challenges, including a recent order from the Delhi High Court for a court-monitored forensic audit regarding the historical dissipation of shareholdings at Fortis Healthcare.
These ongoing legal developments contribute to a climate of uncertainty for stakeholders. While this specific lawsuit in Tokyo has reached a conclusion, the broader narrative regarding the acquisition and the governance of the underlying hospital assets remains a point of interest. Investors tracking this situation may look for further clarity on whether IHH chooses to appeal the Tokyo ruling, as well as any updates regarding the forensic audit process ordered by the Delhi High Court, which continues to influence the sentiment around Fortis Healthcare’s operations.